Microangiopathic hemolytic anemia: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
Lakshmi Gopalakrishnan (talk | contribs)
nocaptcha
10,176 edits
No edit summary
 
MydahSajid (talk | contribs)
1,151 edits
No edit summary
 
(8 intermediate revisions by 4 users not shown)
Line 11: Line 11:
  | MeshID        =  
  | MeshID        =  
}}
}}
{{SI}}
{{Microangiopathic hemolytic anemia}}
{{CMG}}
{{CMG}} {{AE}} {{MSJ}}


{{EH}}
{{SK}} Microangiopathic haemolytic anaemia; MHA


==Overview==
==[[Microangiopathic hemolytic anemia overview|Overview]]==
In [[medicine]] ([[hematology]]) '''microangiopathic hemolytic anemia''' (MAHA) is a subgroup of [[hemolytic anemia]] ([[anemia]], loss of red blood cells through destruction) caused by factors in the small blood vessels. It is identified by the finding of anemia and schistocytes on [[light microscopy|microscopy]] of the [[blood film]].


==Presentation==
==[[Microangiopathic hemolytic anemia historical perspective|Historical Perspective]]==
In diseases such as hemolytic uremic syndrome, disseminated intravascular coagulation, thrombotic thrombocytopenic purpura, as well as malignant hypertension, the endothelial layer of small vessels are damaged with resulting fibrin deposition and platelet aggregation.  As red blood cells travel through these damaged vessels, they are shredded.  The result is red cell fragmentation and intravascular hemolysis.  Under the microscope, damaged red cells have the appearance of schistocytes.


[[Automated analyser]]s (the machines that perform routine [[full blood count]]s in most hospitals) are generally programmed to flag blood films that display red blood cell fragments or ''schistocytes''.
==[[Microangiopathic hemolytic anemia classification|Classification]]==


==Causes==
==[[Microangiopathic hemolytic anemia pathophysiology|Pathophysiology]]==
The most important causes are:
 
* [[Aortic Stenosis]] (most common cause of MAHA)
==[[Microangiopathic hemolytic anemia causes|Causes]]==
* [[Thrombotic thrombocytopenic purpura]] (TTP)
 
* [[Hemolytic uremic syndrome]] (HUS)
==[[Microangiopathic hemolytic anemia differential diagnosis|Differentiating Microangiopathic hemolytic anemia from other Diseases]]==
* [[Disseminated intravascular coagulation]] (DIC)
 
* [[HELLP syndrome]] and [[eclampsia]]
==[[Microangiopathic hemolytic anemia epidemiology and demographics|Epidemiology and Demographics]]==
* [[Heparin-induced thrombocytopenia]] (HIT)
 
* Severe [[glomerulonephritis]]
==[[Microangiopathic hemolytic anemia risk factors|Risk Factors]]==
* Several other rare causes
 
 
 
==[[Microangiopathic hemolytic anemia screening|Screening]]==
 
==[[Microangiopathic hemolytic anemia natural history, complications and prognosis|Natural History, Complications and Prognosis]]==
 
==Diagnosis==
[[Microangiopathic hemolytic anemia history and symptoms| History and Symptoms]] | [[Microangiopathic hemolytic anemia physical examination | Physical Examination]] | [[Microangiopathic hemolytic anemia laboratory findings|Laboratory Findings]] | [[Microangiopathic hemolytic anemia chest x ray|Chest X Ray]] |  [[Microangiopathic hemolytic anemia CT|CT]] | [[Microangiopathic hemolytic anemia MRI|MRI]] | [[Microangiopathic hemolytic anemia ultrasound|Ultrasound]] | [[Microangiopathic hemolytic anemia other imaging findings|Other Imaging Findings]] | [[Microangiopathic hemolytic anemia other diagnostic studies|Other Diagnostic Studies]]
 
==Treatment==
[[Microangiopathic hemolytic anemia medical therapy|Medical Therapy]] |  [[Microangiopathic hemolytic anemia surgery|Surgery]] | [[Microangiopathic hemolytic anemia primary prevention|Primary Prevention]] | [[Microangiopathic hemolytic anemia secondary prevention|Secondary Prevention]] | [[Microangiopathic hemolytic anemia cost-effectiveness of therapy|Cost-Effectiveness of Therapy]] | [[Microangiopathic hemolytic anemia future or investigational therapies|Future or Investigational Therapies]]
 
==Case Studies==
[[Microangiopathic hemolytic anemia case study one|Case#1]]  


==Pathophysiology==
In all causes, the mechanism of MAHA is the formation of a [[fibrin]] mesh due to increased activity of the system of [[coagulation]]. The red blood cells are physically cut by these protein networks, and the fragments are identical to the schistocytes seen on light microscopy.


{{Hematology}}
{{Hematology}}
{{WikiDoc Help Menu}}
{{WikiDoc Sources}}


 
[[Category:Disease]]
[[Category:Disease state]]
[[Category:Hematology]]
[[Category:Hematology]]
[[Category:Nephrology]]
[[Category:Nephrology]]
[[Category:Mature chapter]]
[[Category:Mature chapter]]
{{WikiDoc Help Menu}}
{{WikiDoc Sources}}

Latest revision as of 19:58, 30 January 2021

Microangiopathic hemolytic anemia
ICD-10 D59.4
ICD-9 283.19
DiseasesDB 29721

Microangiopathic hemolytic anemia Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Microangiopathic hemolytic anemia from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Chest X Ray

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Microangiopathic hemolytic anemia On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Microangiopathic hemolytic anemia

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Microangiopathic hemolytic anemia

on Microangiopathic hemolytic anemia

Microangiopathic hemolytic anemia in the news

Blogs on Microangiopathic hemolytic anemia

Directions to Hospitals Treating Microangiopathic hemolytic anemia

Risk calculators and risk factors for Microangiopathic hemolytic anemia

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Mydah Sajid, MD[2]

Synonyms and keywords: Microangiopathic haemolytic anaemia; MHA

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Microangiopathic hemolytic anemia from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms | Physical Examination | Laboratory Findings | Chest X Ray | CT | MRI | Ultrasound | Other Imaging Findings | Other Diagnostic Studies

Treatment

Medical Therapy | Surgery | Primary Prevention | Secondary Prevention | Cost-Effectiveness of Therapy | Future or Investigational Therapies

Case Studies

Case#1


Template:Hematology

Template:WikiDoc Sources

Retrieved from "https://www.wikidoc.org/index.php?title=Microangiopathic_hemolytic_anemia&oldid=1687535"